Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Euro-Med Laboratories PhilippinesPHS:EURO -2.65%82 3-Year EBITDA Growth Rate is 19.90% as of Jun. 2026, which is 286% above its 10-year median of 5.15. GuruFocus rates PHS:EURO with a GF Score™ of 82/100 and a GF Value™ of ₱1.07 (Fairly Valued). The stock has 5 warning signs investors should review. Among 808 Drug Manufacturers companies, Euro-Med Laboratories Philippines ranks better than 67.45% on this metric.
During the past 12 months, Euro-Med Laboratories Philippines's average EBITDA Per Share Growth Rate was 18.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 19.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 12.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 3.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Euro-Med Laboratories Philippines was 19.90% per year. The lowest was -14.70% per year. And the median was 5.15% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Euro-Med Laboratories Philippines 3-Year EBITDA Growth Rate Related Terms
PHS:EURO vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euro-Med Laboratories Philippines's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euro-Med Laboratories Philippines 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euro-Med Laboratories Philippines's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Euro-Med Laboratories Philippines's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 19.90% mean?
Euro-Med Laboratories Philippines (PHS:EURO) has a 3-Year EBITDA Growth Rate of 19.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Euro-Med Laboratories Philippines and its competitors. This is 286% above median its historical median of 5.15. According to the industry distribution chart, Euro-Med Laboratories Philippines ranks #263 out of 808 companies in the Drug Manufacturers industry, placing it in the top 32.5%.
Is Euro-Med Laboratories Philippines' 3-Year EBITDA Growth Rate too high?
Euro-Med Laboratories Philippines' current 3-Year EBITDA Growth Rate of 19.90% is 286% above median its 10-year median of 5.15. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Euro-Med Laboratories Philippines' value of 19.90% is 123.6% above this industry median. Based on the distribution chart, Euro-Med Laboratories Philippines ranks #263 out of 808 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Euro-Med Laboratories Philippines has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Euro-Med Laboratories Philippines' 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euro-Med Laboratories Philippines ranks #263 out of 808 companies for 3-Year EBITDA Growth Rate. This puts Euro-Med Laboratories Philippines in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Euro-Med Laboratories Philippines' value of 19.90% is 123.6% above this benchmark. While the company's 10-year median is 5.15 vs. the industry median of 8.90, Euro-Med Laboratories Philippines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euro-Med Laboratories Philippines's current 3-Year EBITDA Growth Rate of 19.90% is 123.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Euro-Med Laboratories Philippines and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euro-Med Laboratories Philippines's current 3-Year EBITDA Growth Rate is 19.90%, which is 286% above median its own 10-year median of 5.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euro-Med Laboratories Philippines stock overvalued right now?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines (PHS:EURO) is currently considered Fairly Valued. The stock's GF Value™ is ₱1.07, compared to a current price of ₱1.10 — trading 2.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 19.90%, which is 286% above median its 10-year median of 5.15 and 123.6% above the Drug Manufacturers industry median of 8.90. Euro-Med Laboratories Philippines' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Euro-Med Laboratories Philippines (PHS:EURO), the current 3-Year EBITDA Growth Rate is 19.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euro-Med Laboratories Philippines (PHS:EURO) Overvalued in 2026?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines stock appears to be overvalued.
The current stock price of ₱1.10 is trading 2.8% above its estimated GF Value™ of ₱1.07.
GuruFocus considers Euro-Med Laboratories Philippines to be Fairly Valued.
Key valuation signals for PHS:EURO:
3-Year EBITDA Growth Rate: 19.90% (286% above median its 10-year median of 5.15)
GF Value™: ₱1.07 vs. price of ₱1.10 (2.8% above fair value)
Industry Position: 123.6% above the Drug Manufacturers median (#263 of 808)
No single metric tells the full story. See the PHS:EURO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euro-Med Laboratories Philippines Inc is a pharmaceutical-based company that engages in the manufacture of pharmaceutical products such as large and small-volume parenterals and other solutions. The company also manufactures sterile water for injection, and other solutions such as ophthalmic, inhalation, irrigation, and dialysis. The Company also manufactures intravenous fluids in glass bottles, hemodialysis concentrates, ophthalmic products and disinfectants.
82GF Score
Get the complete analysis for PHS:EURO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHS:EURO has been successfully added to your 
